Humanigen Stock Forecast, Price & News

-0.08 (-0.49 %)
(As of 07/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume803,484 shs
Average Volume1.00 million shs
Market Capitalization$959.46 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive HGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for Humanigen and its competitors with MarketBeat's FREE daily newsletter.

Humanigen logo

About Humanigen

Humanigen, Inc., a clinical stage biopharmaceutical company, develops a portfolio of immuno-oncology and immunology monoclonal antibodies in the United States. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes human granulocyte-macrophage colony-stimulating factor, which is in Phase III clinical trial for the treatment of cytokine storm associated with COVID-19; and Phase Ib/II clinical trial as a sequenced therapy in combination with CD19 targeted chimeric antigen receptor T-cell therapies to treat patients with relapsed or refractory B-cell lymphoma, as well as that has completed Phase I clinical trial in patients with chronic myelomonocytic leukemia. It also develops Ifabotuzumab, a humaneered monoclonal antibody that targets EphA3 receptor, which has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies; and HGEN005, an anti-EMR1 monoclonal antibody, which is in pre-clinical stage for the treatment of eosinophilic disorders. Humanigen, Inc. has a clinical collaboration agreement with Kite Pharma, Inc. to conduct a multi-center Phase Ib/II study of Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma; and a cooperative research and development agreement with the Department of Defense to assist in the development of lenzilumab in advance of a potential emergency use authorization for COVID-19. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was incorporated in 2000 and is based in Burlingame, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.19 out of 5 stars

Medical Sector

31st out of 4,434 stocks

Pharmaceutical Preparations Industry

13th out of 1,736 stocks

Analyst Opinion: 4.4Community Rank: 3.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Humanigen (NASDAQ:HGEN) Frequently Asked Questions

Is Humanigen a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Humanigen in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Humanigen stock.
View analyst ratings for Humanigen
or view top-rated stocks.

What stocks does MarketBeat like better than Humanigen?

Wall Street analysts have given Humanigen a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Humanigen wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Humanigen's next earnings date?

Humanigen is scheduled to release its next quarterly earnings announcement on Friday, August 13th 2021.
View our earnings forecast for Humanigen

How were Humanigen's earnings last quarter?

Humanigen, Inc. (NASDAQ:HGEN) released its quarterly earnings data on Thursday, May, 13th. The company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($0.64) by $0.61. The business had revenue of $0.49 million for the quarter.
View Humanigen's earnings history

How has Humanigen's stock been impacted by Coronavirus (COVID-19)?

Humanigen's stock was trading at $16.25 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, HGEN shares have decreased by 0.1% and is now trading at $16.24.
View which stocks have been most impacted by COVID-19

When did Humanigen's stock split? How did Humanigen's stock split work?

Humanigen's stock reverse split on Monday, September 14th 2020. The 1-5 reverse split was announced on Friday, September 4th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 11th 2020. An investor that had 100 shares of Humanigen stock prior to the reverse split would have 20 shares after the split.

What price target have analysts set for HGEN?

8 equities research analysts have issued twelve-month price targets for Humanigen's shares. Their forecasts range from $21.00 to $40.00. On average, they expect Humanigen's share price to reach $31.50 in the next twelve months. This suggests a possible upside of 94.0% from the stock's current price.
View analysts' price targets for Humanigen
or view top-rated stocks among Wall Street analysts.

Who are Humanigen's key executives?

Humanigen's management team includes the following people:
  • Dr. Cameron Durrant M.B.A., M.D., MBA, Chairman & CEO (Age 61, Pay $2.28M)
  • Mr. Timothy E. Morris CPA, CFO & COO (Age 60, Pay $601.84k)
  • Dr. Dale Chappell M.B.A., M.D., MBA, Chief Scientific Officer & Director (Age 51, Pay $479.91k)
  • Dr. Tarek Sahmoud, Chief Medical Officer (Age 60)
  • Dr. Omar Ahmed Pharm.D., Sr. VP of Clinical, Medical & Scientific Affairs
  • Mr. Robert Atwill M.B.A., Head of Asia-Pacific
  • Mr. Edward P. Jordan M.B.A., Chief Commercial Officer (Age 53)
  • Dr. Adrian Kilcoyne M.B.A., M.D., M.P.H., Chief Medical Officer

Who are some of Humanigen's key competitors?

What is Humanigen's stock symbol?

Humanigen trades on the NASDAQ under the ticker symbol "HGEN."

How do I buy shares of Humanigen?

Shares of HGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Humanigen's stock price today?

One share of HGEN stock can currently be purchased for approximately $16.24.

How much money does Humanigen make?

Humanigen has a market capitalization of $959.46 million and generates $310,000.00 in revenue each year. The company earns $-89,540,000.00 in net income (profit) each year or ($2.42) on an earnings per share basis.

How many employees does Humanigen have?

Humanigen employs 10 workers across the globe.

What is Humanigen's official website?

The official website for Humanigen is

Where are Humanigen's headquarters?

Humanigen is headquartered at 533 Airport Boulevard Ste. 400, Burlingame CA, 94010.

How can I contact Humanigen?

Humanigen's mailing address is 533 Airport Boulevard Ste. 400, Burlingame CA, 94010. The company can be reached via phone at 650 243 3100 or via email at [email protected]

This page was last updated on 7/27/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.